HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Luis F. Bonilla Hartzell V. Schaff Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chiu-Pinheiro, C. K. Articles by Schaff, H. V. Search for Related Content PubMed PubMed Citation Articles by Chiu-Pinheiro, C. K. Articles by Schaff, H. V. Related Collections Molecular biology

Ann Thorac Surg 2002;74:1161-1166
© 2002 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Gene transfer to coronary artery bypass conduits

^a Divisions of Endocrinology, Metabolism, Nutrition and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
^b Division of Anesthesiology, Mayo Clinic, Rochester, Minnesota, USA
^c Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA

Accepted for publication May 29, 2002.

* Address reprint requests to Dr Schaff, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA

Background. Gene therapy is a rational approach to prevention of stenosis in saphenous vein grafts used as conduits for coronary artery bypass grafting. To explore this possibility we developed methods for adenoviral-mediated gene transfer to canine saphenous veins.

Methods. During a single procedure, autogenous canine saphenous vein segments were transduced ex vivo and used as coronary artery bypass grafts. The proximal end of each vein was ligated, adenovirus containing the Escherichia coli ß-galactosidase gene (Ad.CMVLacZ) was delivered at titers of 2.5 x 10⁹ or 5 x 10⁹ plaque-forming units (pfu)/mL to the lumen through a distal heparin lock, and the segment was immersed in the viral solution for 1 hour at 37°C. Control segments were exposed to diluent alone in an identical manner. Aortocoronary anastomoses were made using cardiopulmonary bypass. Transgene expression was assessed qualitatively and quantitatively after 3 days.

Results. ß-Galactosidase levels showed a dose-dependent increase: 0.00 ± 0.00 ng/mg total protein for controls; 5.60 ± 2.27 ng/mg total protein for a viral titer of 2.5 x 10⁹ pfu/mL and 11.97 ± 6.14 ng/mg for 5 x 10⁹ pfu/mL. The two dosage groups differed significantly from each other (p = 0.035) and from controls (p = 0.003). X-gal staining demonstrated mostly endothelial and scattered adventitial transgene expression.

Conclusions. Transgene expression after ex vivo gene transfer into saphenous vein grafts in a canine coronary artery bypass model indicates that this method may be useful for delivery of therapeutic genes to prevent or retard vein graft arteriosclerosis.

This article has been cited by other articles:

				J. A. Hata, J. A. Petrofski, J. N. Schroder, M. L. Williams, S. H. Timberlake, A. Pippen, M. T. Corwin, A. K. Solan, A. Jakoi, T. R. Gehrig, et al. Modulation of phosphatidylinositol 3-kinase signaling reduces intimal hyperplasia in aortocoronary saphenous vein grafts J. Thorac. Cardiovasc. Surg., June 1, 2005; 129(6): 1405 - 1413. [Abstract] [Full Text] [PDF]

				F. Sharif, K. Daly, J. Crowley, and T. O'Brien Current status of catheter- and stent-based gene therapy Cardiovasc Res, November 1, 2004; 64(2): 208 - 216. [Abstract] [Full Text] [PDF]

				J. A. Petrofski, J. A. Hata, T. R. Gehrig, S. I. Hanish, M. L. Williams, R. B. Thompson, C. J. Parsa, W. J. Koch, and C. A. Milano Gene delivery to aortocoronary saphenous vein grafts in a large animal model of intimal hyperplasia J. Thorac. Cardiovasc. Surg., January 1, 2004; 127(1): 27 - 33. [Abstract] [Full Text] [PDF]